These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 22896617)

  • 21. DNA prime/MVTT boost regimen with HIV-1 mosaic Gag enhances the potency of antigen-specific immune responses.
    Liu W; Wong YC; Chen SMY; Tang J; Wang H; Cheung AKL; Chen Z
    Vaccine; 2018 Jul; 36(31):4621-4632. PubMed ID: 29961605
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Novel adenovirus vector-based vaccines for HIV-1.
    Barouch DH
    Curr Opin HIV AIDS; 2010 Sep; 5(5):386-90. PubMed ID: 20978378
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Deletion of specific immune-modulatory genes from modified vaccinia virus Ankara-based HIV vaccines engenders improved immunogenicity in rhesus macaques.
    Garber DA; O'Mara LA; Gangadhara S; McQuoid M; Zhang X; Zheng R; Gill K; Verma M; Yu T; Johnson B; Li B; Derdeyn CA; Ibegbu C; Altman JD; Hunter E; Feinberg MB
    J Virol; 2012 Dec; 86(23):12605-15. PubMed ID: 22973033
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A Novel Immunogen Selectively Eliciting CD8
    Ishii H; Terahara K; Nomura T; Takeda A; Okazaki M; Yamamoto H; Tokusumi T; Shu T; Matano T
    J Virol; 2020 Mar; 94(8):. PubMed ID: 32024773
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Recombinant vector-induced HIV/SIV-specific CD4+ T lymphocyte responses in rhesus monkeys.
    Sun Y; Santra S; Buzby AP; Mascola JR; Nabel GJ; Letvin NL
    Virology; 2010 Oct; 406(1):48-55. PubMed ID: 20667574
    [TBL] [Abstract][Full Text] [Related]  

  • 26. HIV/AIDS Vaccine Candidates Based on Replication-Competent Recombinant Poxvirus NYVAC-C-KC Expressing Trimeric gp140 and Gag-Derived Virus-Like Particles or Lacking the Viral Molecule B19 That Inhibits Type I Interferon Activate Relevant HIV-1-Specific B and T Cell Immune Functions in Nonhuman Primates.
    García-Arriaza J; Perdiguero B; Heeney JL; Seaman MS; Montefiori DC; Yates NL; Tomaras GD; Ferrari G; Foulds KE; Roederer M; Self SG; Borate B; Gottardo R; Phogat S; Tartaglia J; Barnett SW; Burke B; Cristillo AD; Weiss DE; Lee C; Kibler KV; Jacobs BL; Wagner R; Ding S; Pantaleo G; Esteban M
    J Virol; 2017 May; 91(9):. PubMed ID: 28179536
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A study of vaccine-induced immune pressure on breakthrough infections in the Phambili phase 2b HIV-1 vaccine efficacy trial.
    Hertz T; Logan MG; Rolland M; Magaret CA; Rademeyer C; Fiore-Gartland A; Edlefsen PT; DeCamp A; Ahmed H; Ngandu N; Larsen BB; Frahm N; Marais J; Thebus R; Geraghty D; Hural J; Corey L; Kublin J; Gray G; McElrath MJ; Mullins JI; Gilbert PB; Williamson C
    Vaccine; 2016 Nov; 34(47):5792-5801. PubMed ID: 27756485
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19).
    Barouch DH; Tomaka FL; Wegmann F; Stieh DJ; Alter G; Robb ML; Michael NL; Peter L; Nkolola JP; Borducchi EN; Chandrashekar A; Jetton D; Stephenson KE; Li W; Korber B; Tomaras GD; Montefiori DC; Gray G; Frahm N; McElrath MJ; Baden L; Johnson J; Hutter J; Swann E; Karita E; Kibuuka H; Mpendo J; Garrett N; Mngadi K; Chinyenze K; Priddy F; Lazarus E; Laher F; Nitayapan S; Pitisuttithum P; Bart S; Campbell T; Feldman R; Lucksinger G; Borremans C; Callewaert K; Roten R; Sadoff J; Scheppler L; Weijtens M; Feddes-de Boer K; van Manen D; Vreugdenhil J; Zahn R; Lavreys L; Nijs S; Tolboom J; Hendriks J; Euler Z; Pau MG; Schuitemaker H
    Lancet; 2018 Jul; 392(10143):232-243. PubMed ID: 30047376
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The improved antibody response against HIV-1 after a vaccination based on intrastructural help is complemented by functional CD8+ T cell responses.
    Storcksdieck genannt Bonsmann M; Niezold T; Hannaman D; Überla K; Tenbusch M
    Vaccine; 2016 Apr; 34(15):1744-51. PubMed ID: 26945099
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Superiority in Rhesus Macaques of Targeting HIV-1 Env gp140 to CD40 versus LOX-1 in Combination with Replication-Competent NYVAC-KC for Induction of Env-Specific Antibody and T Cell Responses.
    Zurawski G; Shen X; Zurawski S; Tomaras GD; Montefiori DC; Roederer M; Ferrari G; Lacabaratz C; Klucar P; Wang Z; Foulds KE; Kao SF; Yu X; Sato A; Yates NL; LaBranche C; Stanfield-Oakley S; Kibler K; Jacobs B; Salazar A; Self S; Fulp W; Gottardo R; Galmin L; Weiss D; Cristillo A; Pantaleo G; Levy Y
    J Virol; 2017 May; 91(9):. PubMed ID: 28202751
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Control of HIV-1 replication in vitro by vaccine-induced human CD8(+) T cells through conserved subdominant Pol epitopes.
    Ahmed T; Borthwick NJ; Gilmour J; Hayes P; Dorrell L; Hanke T
    Vaccine; 2016 Feb; 34(9):1215-24. PubMed ID: 26784683
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Gag and env conserved element CE DNA vaccines elicit broad cytotoxic T cell responses targeting subdominant epitopes of HIV and SIV Able to recognize virus-infected cells in macaques.
    Hu X; Lu Z; Valentin A; Rosati M; Broderick KE; Sardesai NY; Marx PA; Mullins JI; Pavlakis GN; Felber BK
    Hum Vaccin Immunother; 2018; 14(9):2163-2177. PubMed ID: 29939820
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Adenovirus-based HIV-1 vaccine candidates tested in efficacy trials elicit CD8+ T cells with limited breadth of HIV-1 inhibition.
    Hayes PJ; Cox JH; Coleman AR; Fernandez N; Bergin PJ; Kopycinski JT; Nitayaphan S; Pitisuttihum P; de Souza M; Duerr A; Morgan C; Gilmour JW
    AIDS; 2016 Jul; 30(11):1703-12. PubMed ID: 27088318
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Preclinical evaluation of HIV-1 therapeutic ex vivo dendritic cell vaccines expressing consensus Gag antigens and conserved Gag epitopes.
    Niu L; Termini JM; Kanagavelu SK; Gupta S; Rolland MM; Kulkarni V; Pavlakis GN; Felber BK; Mullins JI; Fischl MA; Stone GW
    Vaccine; 2011 Mar; 29(11):2110-9. PubMed ID: 21241732
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Design and evaluation of optimized artificial HIV-1 poly-T cell-epitope immunogens.
    Reguzova A; Antonets D; Karpenko L; Ilyichev A; Maksyutov R; Bazhan S
    PLoS One; 2015; 10(3):e0116412. PubMed ID: 25786238
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity.
    Shiver JW; Fu TM; Chen L; Casimiro DR; Davies ME; Evans RK; Zhang ZQ; Simon AJ; Trigona WL; Dubey SA; Huang L; Harris VA; Long RS; Liang X; Handt L; Schleif WA; Zhu L; Freed DC; Persaud NV; Guan L; Punt KS; Tang A; Chen M; Wilson KA; Collins KB; Heidecker GJ; Fernandez VR; Perry HC; Joyce JG; Grimm KM; Cook JC; Keller PM; Kresock DS; Mach H; Troutman RD; Isopi LA; Williams DM; Xu Z; Bohannon KE; Volkin DB; Montefiori DC; Miura A; Krivulka GR; Lifton MA; Kuroda MJ; Schmitz JE; Letvin NL; Caulfield MJ; Bett AJ; Youil R; Kaslow DC; Emini EA
    Nature; 2002 Jan; 415(6869):331-5. PubMed ID: 11797011
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Altering an artificial Gagpolnef polyprotein and mode of ENV co-administration affects the immunogenicity of a clade C HIV DNA vaccine.
    Böckl K; Wild J; Bredl S; Kindsmüller K; Köstler J; Wagner R
    PLoS One; 2012; 7(4):e34723. PubMed ID: 22509350
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Correlation of immunogenicities and in vitro expression levels of recombinant modified vaccinia virus Ankara HIV vaccines.
    Wyatt LS; Earl PL; Vogt J; Eller LA; Chandran D; Liu J; Robinson HL; Moss B
    Vaccine; 2008 Jan; 26(4):486-93. PubMed ID: 18155813
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Virus-like vaccines against HIV/SIV synergize with a subdominant antigen T cell vaccine.
    Schwerdtfeger M; Andersson AC; Neukirch L; Holst PJ
    J Transl Med; 2019 May; 17(1):175. PubMed ID: 31126293
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Env-2dCD4 S60C complexes act as super immunogens and elicit potent, broadly neutralizing antibodies against clinically relevant human immunodeficiency virus type 1 (HIV-1).
    Killick MA; Grant ML; Cerutti NM; Capovilla A; Papathanasopoulos MA
    Vaccine; 2015 Nov; 33(46):6298-306. PubMed ID: 26432912
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.